2008-09-27 18:09:02 - Successful Pharmabiotech Alliance Strategies - Driving synergies - a new market research report on http://www.companiesandmarkets.com

www.companiesandmarkets.com/Summary-Market-Report/Successful-Pha ..

Over the past few years, alliances between pharmaceutical (“pharma”) and biotechnology (“biotech”) companies have become common, with hundreds of relationships currently in place to develop drugs for virtually all of the highest priority conditions. For pharmaceutical companies, this is a direct result of rising imperatives to develop new products, coupled with rapidly escalating R&D costs. While pharmaceutical companies continue to

experience patent expirations that reduce revenue, pipelines are shrinking while the average cost of bringing each new drug to market has risen from about $100m in 1990 to nearly $1b in 2008. For biotechs, alliances provide much-needed funding without which many companies would be unable to continue their R&D activities.

www.companiesandmarkets.com/Summary-Market-Report/Successful-Pha ..